Australia’s Provisional Approval Pathway Prompts Industry Concerns Over Data Provision
Executive Summary
Pharmaceutical industry responses to a consultation by Australia’s Therapeutic Goods Administration on a provisional approval pathway have revealed concerns over whether companies will be able to provide adequate data. Companies have also advised the TGA to look to other regulators, including the European Medicines Agency, for inspiration.